Novaremed AG's Seed Round

Novaremed AG raised a round of funding on April 17, 2018.

Novaremed AG is a clinical-stage Swiss biopharmaceutical company developing an orally active, small molecule (NRD.E1) to treat Diabetic Neuropathic Pain.…

Articles about Novaremed AG's Seed Round: